Flavocure Biotech Announces Orphan Designation Granted by FDA for Caflanone (FBL-03G) in Pancreatic Cancer

Baltimore, Maryland–(Newsfile Corp. – October 3, 2019) – Flavocure Biotech, Inc. (“Flavocure”) a drug discovery and development company, announced today that the United States Food and Drug Administration (FDA) on September 25, 2019 granted Orphan drug status to its lead drug candidate, Caflanone (FBL-03G) for the treatment of Pancreatic Cancer. “We are very pleased to … Read more

Are you 18 or older? The law requires you to be 18 years of age or older to enter this website. Please verify your age to view the content, or click "Exit" to leave.